ArticleCureus2025
Hyperlipidemic Abdominal Crisis: A Unique Presentation of Isolated Severe Hypertriglyceridemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe hypertriglyceridemia, defined as levels >1000 mg/dL, is a condition that manifests in various ways including hyperlipidemic abdominal crisis (HLAC) with risk of progression to pancreatitis. We discuss the unique presentation of HLAC in a 50-year-old patient whose diagnosis remained unclear on initial presentation. Initial laboratory evaluation and imaging were unrevealing, but laboratory personnel relayed concerns for lipemic blood samples, prompting a lipid panel in the Emergency Department (ED). Triglycerides measured 2562 mg/dL helping to confirm probable diagnosis of HLAC. After consultation with Endocrinology, the patient was admitted for an insulin infusion with glucose-containing maintenance fluids to help treat the very severe hypertriglyceridemia. The patient was discharged in good condition on hospital day 3 with triglyceride levels down to 405 mg/dL and prescribed a new oral agent, Icosapent ethyl at 2 g orally daily. Clinicians evaluating patients for acute abdominal complaints should be alert to the possible diagnosis of HLAC given the potential for deterioration to pancreatitis and concomitant complications. Prompt management with an insulin infusion or plasmapheresis along with appropriate consultation with specialists is crucial to mitigate the risk of adverse outcomes in this rare abdominal emergency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.